BridGene Biosciences

About BridGene Biosciences

BridGene Biosciences is focused on discovering novel therapeutic targets and quality leads to accelerate therapeutic innovation and improve human health. The company aims to bridge undruggable targets with precision medicines using its proprietary technologies.

Products & Services

IMTAC™ Platform:A cutting-edge platform combining covalent chemistry, chemical proteomics, and quantitative mass spectrometry for proteome-wide screening, target-focused screening, and drug development against undruggable targets.

Pipeline Products:Includes drug candidates like BGC-515 (a novel TEAD inhibitor for advanced solid tumors) and BGI-9004, with ongoing clinical and preclinical studies.

Specialties

Chemoproteomics Covalent Chemistry Quantitative Mass Spectrometry Drug Discovery for Undruggable Targets Precision Oncology Immunology Neurology

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Series B+ T: - FT: Series B+	A: 28000000 MR: - FA: 28 million FAN: 28000000	D: 2025-10-16 FD: 2025-10-16	5 investors

Series B+ Latest

2025-10-16

$28.0M

5 investors (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

P

Ping Cao

CEO

I

Irene Yuan

Chief Operating Officer

J

Jeremy Barton

Chief Medical Officer

P

Petr Jansa

Head of Chemistry

A

Anna Chen

Executive Director - Biology

S

Shirley Guo

Senior Director of Biology

View 10 more team members with Pro

Unlock Full Team Directory

Recent News